壳聚糖微囊胰岛素通过调节糖尿病大鼠 COX-2 和 VCAM-1 的表达来缓解肠系膜微循环功能障碍。
Chitosan-microcapsulated insulin alleviates mesenteric microcirculation dysfunction via modulating COX-2 and VCAM-1 expression in rats with diabetes mellitus.
机构信息
Department of Emergency Medicine, The First Hospital of Jiaxing, Jiaxing 314001, Zhejiang Province, China,
出版信息
Int J Nanomedicine. 2018 Oct 25;13:6829-6837. doi: 10.2147/IJN.S174030. eCollection 2018.
BACKGROUND
The study of the experiment was to display the therapeutic function of insulin-loaded chitosan (insulin/chitosan) on mesenteric microcirculation via down-regulating cyclooxygenase-2 (COX-2) and vascular cell adhesion molecule (VCAM-1) expressions in rats with diabetes mellitus (DM) as compared to free insulin.
METHODS
Diabetic rats were administrated with 24 U/kg insulin or 120 U/kg insulin/chitosan compounds. The blood and mesenteriums were collected, blood glucose levels, arteriole velocity, arteriole diameter, venular diameter, and hemodiapedesis were measured, and COX-2, VCAM-1 expressions were measured in mesenteriums tissues.
RESULTS
Both insulin and insulin/chitosan administration decreased blood glucose and improved the state of mesenteric microcirculation through down-regulating COX-2 and VCAM-1 expressions as compared to DM groups, while insulin/chitosan remarkably augmented this functions.
CONCLUSION
Chitosan-microcapsulated insulin alleviates mesenteric microcirculation dysfunction via modulating COX-2 and VCAM-1 expressions in rats with DM.
背景
本实验旨在研究载胰岛素壳聚糖（胰岛素/壳聚糖）通过下调糖尿病（DM）大鼠肠系膜组织中环氧化酶-2（COX-2）和血管细胞黏附分子（VCAM-1）的表达，发挥其对肠系膜微循环的治疗作用，并与游离胰岛素进行比较。
方法
给予糖尿病大鼠 24 U/kg 胰岛素或 120 U/kg 胰岛素/壳聚糖复合物。采集血液和肠系膜组织，测量血糖水平、微动脉速度、微动脉直径、小静脉直径和血液渗出情况，并测量肠系膜组织中 COX-2、VCAM-1 的表达。
结果
与 DM 组相比，胰岛素和胰岛素/壳聚糖给药均能降低血糖，并通过下调 COX-2 和 VCAM-1 的表达改善肠系膜微循环状态，而胰岛素/壳聚糖则显著增强了这一作用。
结论
壳聚糖微囊化胰岛素通过调节 DM 大鼠 COX-2 和 VCAM-1 的表达来缓解肠系膜微循环功能障碍。
Zotero 插件